Product Description
Inheriting the unique mechanism of action from ALTB-168, ALTB-268 is subtly designed as a multiple-valence molecule to achieve a better efficacy. From preliminary experimental results, ALTB-268 exhibits not only comparable preliminary safety profiles, but also improved potency in eliminating chronic pathogenic T cells. Therefore, a lower dosage to obtain an equal efficacy in clinical is expected. (Sourced from: https://www.altrubio.com/altrubio/en/product/detail/ALTB268)
Mechanisms of Action: PSGL-1 Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AltruBio
Company Location: Western America
Company Founding Year: 2001
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Puerto Rico, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colitis, Ulcerative
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07350577 |
ALTB-268-102 | P1 |
Active, not recruiting |
Colitis, Ulcerative |
2026-09-26 |
50% |
2026-05-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06109441 |
ALTB-268-201 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2026-03-05 |
12% |
2026-05-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/23/2025 |
News Article |
AltruBio Presents New Preclinical Data at FOCIS 2025 Demonstrating ALTB-268's Efficacy in T Cell-Mediated Inflammatory Models |
|
12/03/2024 |
News Article |
AltruBio Announces Formation of Scientific Advisory Board |
|
11/12/2024 |
News Article |
AltruBio to Participate in the Upcoming Jefferies London Healthcare Conference and the Piper Sandler 36th Annual Healthcare Conference |
|
10/28/2024 |
News Article |
AltruBio Presents New In Vivo data for ALTB-268 at the 9th FIMSA 2024 Congress |